Cell therapy trials for “regenerating” chronically failing hearts have entailed the
use of bone marrow-derived cells and skeletal myoblasts. In the case of bone marrow
cells, surgical injections of the mononuclear fraction combined with coronary artery
bypass surgery have failed to show any substantial benefit. More successful outcomes
have been reported after catheter transfer of these cells or intraoperative epicardial
injections of CD133+ progenitors, probably because of angiogenesis. In the case of skeletal myoblasts,
the surgical MAGIC trial has not achieved its primary efficacy end point but the highest
dose of myoblasts resulted in a significant anti-remodeling effect compared with the
placebo group. The results of the catheter-based myoblast delivery trials have been
more disappointing.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
S7-1
Identification
Copyright
© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
